Immunosuppression in IgA nephropathy: how certain are we?

Kidney Int. 2016 Jan;89(1):9-11. doi: 10.1016/j.kint.2015.11.013.

Abstract

The optimal role of immunosuppressive therapy in the treatment of IgA nephropathy is controversial. Results of a recently completed randomized controlled trial provide strong support for comprehensive supportive care rather than immunosuppressive therapy in patients at high risk for progression.

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Glomerular Filtration Rate
  • Glomerulonephritis, IGA / drug therapy*
  • Glomerulonephritis, IGA / physiopathology
  • Glomerulonephritis, IGA / therapy
  • Humans
  • Hypertension / drug therapy
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Proteinuria / drug therapy
  • Randomized Controlled Trials as Topic
  • Renin-Angiotensin System / drug effects

Substances

  • Antihypertensive Agents
  • Immunosuppressive Agents